Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.55
+0.06 (0.31%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Apellis Pharmaceuticals Employees
As of December 31, 2024, Apellis Pharmaceuticals had 710 total employees, including 705 full-time and 5 part-time employees. The number of employees increased by 4 or 0.57% compared to the previous year.
Employees
710
Change (1Y)
4
Growth (1Y)
0.57%
Revenue / Employee
$1,100,517
Profits / Employee
-$278,701
Market Cap
2.20B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
APLS News
- 4 days ago - Apellis Announces Craig Wheeler to Join the Board of Directors - GlobeNewsWire
- 23 days ago - FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Benzinga
- 24 days ago - Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire
- 7 weeks ago - Apellis Pharmaceuticals: A Mixed Bag - Seeking Alpha
- 7 weeks ago - Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga
- 7 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire